Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients

Gary E. Raskob, PhD; Alex C. Spyropoulos, MD; Alexander T. Cohen, MBBS, MSc, MD; Jeffrey I. Weitz, MD; Walter Ageno, MD; Yoriko De Sanctis, MS; Wentao Lu, PhD; Jianfeng Xu, PhD; John Albanese, MBA; Chiara Sugarmann, BSN, MSHS; Traci Weber, MA; Concetta Lipardi, MD, PhD; Theodore E. Spiro, MD; Elliot S. Barnathan, MD

BACKGROUND: Asymptomatic proximal deep vein thrombosis (DVT) is an end point frequently used to evaluate the efficacy of anticoagulant thromboprophylaxis in medical patients. Recently, the clinical relevance of asymptomatic DVT has been challenged.

METHODS AND RESULTS: The objective of this study was to evaluate the relationship between asymptomatic proximal DVT and all-cause mortality (ACM) using a cohort analysis of a randomized trial for the prevention of venous thromboembolism (VTE) in acutely ill medical patients. Patients who received at least 1 dose of study drug and had an adequate compression ultrasound examination of the legs on either day 10 or day 35 were categorized into 1 of 3 cohorts: no VTE, asymptomatic proximal DVT, or symptomatic DVT. Cox proportional hazards model, with adjustment for significant independent predictors of mortality, were used to compare the incidences of ACM. Of the 7036 patients, 6776 had no VTE, 236 had asymptomatic DVT, and 24 had symptomatic VTE. The incidence of ACM was 4.8% in patients without VTE. Both asymptomatic proximal DVT (mortality, 11.4%; hazard ratio [HR], 2.31; 95% CI, 1.52–3.51; \( P < 0.0001 \)) and symptomatic VTE (mortality, 29.2%; HR, 9.42; 95% CI, 4.18–21.20; \( P < 0.0001 \)) were independently associated with significant increases in ACM. The analysis was post hoc, and ultrasound results were not available for all patients. Adjustment for baseline variables significantly associated with ACM may not fully compensate for differences.

CONCLUSIONS: Asymptomatic proximal DVT is associated with higher ACM than no VTE and remains a relevant end point to evaluate the efficacy of anticoagulant thromboprophylaxis in medical patients.

REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00571649.

Key Words: medically ill ■ mortality ■ proximal DVT
the use of proximal DVT as an end point in clinical trials evaluating the effectiveness of anticoagulant thromboprophylaxis. Previous studies of thromboprophylaxis in patients hospitalized for acute medical illness have suggested that the presence of asymptomatic proximal DVT is associated with subsequent increased mortality.6,7

The MAGELLAN (Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Acutely Ill Medical Patients Comparing Rivaroxaban With Enoxaparin) study was a large randomized, double-blind clinical trial evaluating thromboprophylaxis in patients admitted to the hospital with acute medical illness.6 The study protocol required all patients to undergo routine compression ultrasonography of the legs performed on day 10 and day 35 after randomization. All patients were followed to day 90. All ultrasound results, and all suspected episodes of VTE, myocardial infarction, stroke, bleeding, and all deaths were adjudicated by a central independent clinical events committee, according to prespecified criteria9 and without knowledge of the patient’s treatment group.

The trial was conducted in accordance with the Declaration of Helsinki and local regulations. The protocol was approved by the relevant local institutional review boards and ethics committees, and written informed consent was obtained from each patient.

Statistical Analysis
This analysis was defined post hoc to test the hypothesis identified from previously published literature5,7 that the presence of asymptomatic proximal DVT is associated with increased mortality from all causes. The population for the analysis consisted of all patients who received at least 1 dose of the study drug and had an adequate ultrasound result at either day 10±4 or day 35±4 (modified intent-to-treat population). Patients were categorized into

Nonstandard Abbreviations and Acronyms

| Acronym | Description |
|---------|-------------|
| ACM     | all-cause mortality |

CLINICAL PERSPECTIVE

What Is New?
- Among patients hospitalized with acute medical illness, those with asymptomatic proximal deep vein thrombosis have a >2-fold increase in mortality compared with patients without venous thromboembolism.

What Are the Clinical Implications?
- Asymptomatic proximal deep vein thrombosis is an indicator of clinically important venous thromboembolic disease and remains a useful outcome for evaluating the efficacy of thromboprophylaxis in patients with acute medical illness.

METHODS

Data Sharing Statement
At present, the sponsor’s policy is to share data after regulatory approval in accordance with the policy of its codevelopment partner. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the criteria for listing studies and other relevant information is provided in the codevelopment partner’s section of the portal.

Study Design
The results of the MAGELLAN trial (NCT00571649) have been reported in detail.8 Briefly, this study, which included 8101 acutely ill medical patients, compared thromboprophylaxis with 10 mg of rivaroxaban daily, started in hospital and continued for a total of 35±4 days, with enoxaparin (40 mg daily) given for 10±4 days) followed by placebo. The primary end point was the composite of asymptomatic proximal DVT, symptomatic DVT, pulmonary embolism, or VTE-related death. Eligible patients were adults at least 40 years of age hospitalized for an acute medical illness (ie, heart failure, active cancer, acute ischemic stroke, acute infectious and inflammatory disease, and acute respiratory insufficiency) who were at risk for VTE because of moderate or severe immobility and who had additional risk factors for VTE, including prolonged immobilization, age ≥75 years, history of cancer, history of VTE, history of heart failure, thrombophilia, acute infectious disease contributing to the hospitalization, and body mass index ≥35 kg/m². The study protocol required all patients to undergo routine compression ultrasonography of both legs on day 10±4 and day 35±4 after randomization. All patients were followed to day 90. All ultrasound results, and all suspected episodes of VTE, myocardial infarction, stroke, bleeding, and all deaths were adjudicated by a central independent clinical events committee, according to prespecified criteria9 and without knowledge of the patient’s treatment group.

The trial was conducted in accordance with the Declaration of Helsinki and local regulations. The protocol was approved by the relevant local institutional review boards and ethics committees, and written informed consent was obtained from each patient.

Statistical Analysis
This analysis was defined post hoc to test the hypothesis identified from previously published literature5,7 that the presence of asymptomatic proximal DVT is associated with increased mortality from all causes. The population for the analysis consisted of all patients who received at least 1 dose of the study drug and had an adequate ultrasound result at either day 10±4 or day 35±4 (modified intent-to-treat population). Patients were categorized into
1 of 3 mutually exclusive cohorts: (1) those without VTE; (2) those with asymptomatic proximal DVT documented by compression ultrasonography; or (3) those with symptomatic VTE (including symptomatic DVT of the lower extremity and/or symptomatic nonfatal pulmonary embolism), occurring at any time during the study and confirmed by the clinical events committee. Patients who had both asymptomatic DVT and a subsequent symptomatic VTE were counted in the asymptomatic DVT cohort.

Baseline covariates (age, sex, race, body mass index, diabetes mellitus, creatinine clearance, history of VTE, history of cancer, history of anemia, assigned treatment group) and the following reasons for hospitalization: heart failure, acute ischemic stroke, acute infectious disease, inflammatory disease, acute respiratory insufficiency, were tested for significant association with ACM ($P<0.05$) using a Cox proportional hazards model. The final Cox model included the time from the first thromboembolic event to death as the response variable and the 3 baseline covariates (history of cancer, body mass index, history of anemia) that were significantly ($P<0.05$) associated with mortality, as well as the reasons for hospitalization (heart failure, acute ischemic stroke, inflammatory disease, acute respiratory insufficiency) that were significant ($P<0.05$) as the predictor variables. The analysis compared the risk of mortality from all causes through the day 90 visit across the 3 cohorts. The hazard ratios (HRs) shown in the Results are adjusted HRs for the predictor variables listed above fitted by the final Cox model. A Schoenfeld residuals-based test for the independence between residuals and time was used to check the proportional hazards assumption for each covariate included in the Cox model fitting. For both the full model and the final model, the test was not statistically significant for each of the covariates, and the global test was also not statistically significant. Therefore, the assumption of proportionality was supported. Kaplan-Meier plots were used to display survival probabilities and cumulative mortality (without adjusting for the predictor variables) over time from the first VTE event or from the time of the first ultrasound in those without VTE.

**RESULTS**

**Baseline Characteristics**

Of the 8101 patients enrolled in the MAGELLAN study, 7036 (86.8%) were included in the combined day 10/day 35 modified intent-to-treat analysis set. The flow of all randomized patients through the analysis is shown in Figure 1. Of the 7036 patients included in the analysis, 6776 patients (96.3%) were included in the cohort without VTE, 236 patients (3.4%) in the cohort with symptomatic VTE, and 24 patients (0.3%) in the cohort with asymptomatic VTE (Figure 1).

The baseline demographic and clinical characteristics of the patients in each of the cohorts are shown in Table 1. Follow-up through day 90 with documentation of mortality status was completed in 227 patients (96.2%) in the asymptomatic proximal DVT cohort, 24 patients (100%) in the symptomatic VTE cohort, and in 6627 patients (97.8%) in the cohort without VTE. Patients who did not complete the day 90 follow-up were censored at the time of their last follow-up, which documented their mortality status.

**Efficacy Outcomes**

The cumulative incidences of mortality from all causes were 11.4%, 29.2%, and 4.8% in the cohorts with asymptomatic DVT, symptomatic VTE, and no VTE, respectively ($P<0.0001$). Compared with the 4.8% incidence of ACM in the cohort without VTE, asymptomatic proximal DVT was associated with a statistically significant increase in ACM (HR, 2.31; 95% CI, 1.52–3.51; $P<0.0001$). Likewise, the presence of symptomatic VTE was also associated with a statistically significant increase in ACM (HR, 9.42; 95% CI, 4.18–21.20; $P<0.0001$). The Kaplan-Meier plots of the time to the occurrence of death for each of the 3 cohorts are shown in Figure 2. The number and causes of death in each of the cohorts are listed in Table 2.

Of the 236 patients with asymptomatic proximal DVT, 106 patients (44.9%) received anticoagulant treatment after the diagnosis. By comparison, anticoagulant treatment after diagnosis was given to 21 of the 24 patients (87.5%) with symptomatic VTE, and to 768 of the 6776 patients (11.3%) without VTE.

A plot comparing survival after the diagnosis of asymptomatic proximal DVT with the survival in the cohort without evidence of VTE is shown in Figure 3A.
The comparison of these survival curves was statistically significant ($P<0.0001$).

**DISCUSSION**

The results of this analysis of patients hospitalized for acute medical illness indicate that the presence of asymptomatic proximal DVT is associated with a 2-fold increased mortality from all causes through day 90 after randomization. The mortality among those in whom asymptomatic DVT was detected was 11.4%, compared with 4.8% among those without evidence of VTE (HR, 2.31; 95% CI, 1.52–3.51; $P<0.0001$). Thus, the presence of asymptomatic proximal DVT is an indicator of clinically important disease and a marker of a worse prognosis. The mortality among patients with symptomatic VTE was also significantly increased, with a nearly 10-fold increase (29.2%; HR, 9.42; 95% CI, 4.18–21.20; $P<0.0001$). The time to death curves show early and continued separation.
for both cohorts of patients with documented thromboembolism compared with the patients without evidence of VTE (Figure 2).

The causes of the excess deaths among patients with asymptomatic proximal DVT compared with those without VTE included cancer and infectious diseases such as pneumonia (Table 2), conditions known to be associated with an increased risk of VTE.\textsuperscript{10,11} Excluding pulmonary embolism as a contributing cause of death among medical patients is often difficult in the absence of autopsy examination.\textsuperscript{12} Multiple autopsy studies have established that

### Table 2. Causes of Death Adjudicated by the Clinical Events Committee

| Cause of Death                              | Asymptomatic Proximal DVT N=236 n (%) | Symptomatic VTE N=24 n (%) | No VTE N=6776 n (%) |
|---------------------------------------------|---------------------------------------|----------------------------|---------------------|
| All-cause mortality                         | 27 (11.44)                            | 7 (29.17)                  | 322 (4.75)          |
| Cardiovascular                              | 4 (1.69)                              | 2 (8.33)                   | 65 (0.96)           |
| Pulmonary embolism                          | 0                                     | 1 (4.17)                   | 2 (0.03)            |
| Pulmonary embolism cannot be excluded       | 4 (1.69)                              | 1 (4.17)                   | 74 (1.09)           |
| Bleeding                                    | 0                                     | 0                          | 9 (0.13)            |
| Other                                       | 19 (8.05)                             | 3 (12.5)                   | 172 (2.54)          |
| Amyloidosis                                 | 1 (0.4)                               | 0                          | 0                   |
| Amyotrophic lateral sclerosis               | 0                                     | 0                          | 1 (0.01)            |
| Cachexia                                    | 0                                     | 0                          | 1 (0.01)            |
| Cancer                                      | 9 (3.8)                               | 1 (4.2)                    | 65 (1.0)            |
| Dehydration                                 | 0                                     | 0                          | 1 (0.01)            |
| Infectious disease                          | 7 (3.0)                               | 1 (4.2)                    | 52 (0.8)            |
| Multiple organ failure                      | 0                                     | 0                          | 2 (0.03)            |
| Not reported                                | 0                                     | 0                          | 2 (0.03)            |
| Respiratory failure                         | 2 (0.8)                               | 1 (4.2)                    | 44 (0.6)            |
| Parkinson disease                           | 0                                     | 0                          | 1 (0.01)            |
| Renal failure                               | 0                                     | 0                          | 1 (0.01)            |
| Septicemia                                  | 0                                     | 0                          | 1 (0.01)            |
| Unknown cause of death                      | 0                                     | 0                          | 1 (0.01)            |

DVT indicates deep vein thrombosis; and VTE, venous thromboembolism.
the diagnosis of pulmonary embolism is often unsuspected ante mortem.\textsuperscript{12} About one-half of the patients with asymptomatic proximal DVT in our study were not given anticoagulant therapy. Therefore, it is likely that pulmonary embolism may have been a contributing factor to death in many of these patients.

Our results are consistent with those of 2 previous studies\textsuperscript{6,7} in patients hospitalized with medical illness, which provided the basis for our hypothesis of an increased mortality (decreased survival) associated with the diagnosis of asymptomatic proximal DVT. Both studies documented significantly decreased survival in patients with asymptomatic proximal DVT, as shown in the survival curves in Figure 3B and 3C. The results of our analysis (Figure 3A) are remarkably consistent with the results of these 2 studies.\textsuperscript{6,7} In contrast to proximal DVT, asymptomatic distal DVT was not associated with significantly reduced survival compared with patients without DVT in the PREVENT (Prevention of Recurrent Venous Thromboembolism) study\textsuperscript{6} (Figure 3B). This finding provides support for the conclusion that it is the proximal site of DVT that confers the poor prognosis of increased mortality. It is well established that thrombosis of the proximal deep veins (popliteal, femoral, or iliac) is much more likely to lead to clinically important pulmonary embolism than thrombosis confined to the distal deep veins (calf vein thrombosis).\textsuperscript{5}

During the past decade, evidence-based practice guidelines have recommended against the use of asymptomatic proximal DVT as a clinically important outcome in the benefit-risk assessment of thromboprophylaxis in medical patients. This recommendation should be reconsidered in view of the consistent data that asymptomatic proximal DVT is associated with increased mortality in this patient population. We agree with Bounaumeaux and Agnelli, who made the case for patients undergoing orthopedic surgery, that asymptomatic thrombosis may be clinically relevant and that asymptomatic venographically detected thrombosis is a clinically relevant outcome.\textsuperscript{13} As the source of most episodes of fatal pulmonary embolism,\textsuperscript{5} asymptomatic proximal DVT is not a surrogate outcome but, rather, part of the natural history continuum of VTE, and remains an appropriate outcome for evaluation of thromboprophylaxis.

Our analysis has strengths and limitations. Strengths include the relatively large sample size, the objective documentation of the presence or absence of VTE, the blinded central adjudication of all outcomes, and the low rate of loss to follow-up. Limitations include the post hoc nature of the analysis and the fact that 962 of the 7998 patients (12%) included in the trial had inadequate ultrasound results. Although adjustment was done for baseline variables that were significantly associated with ACM, such adjustment may not fully compensate for baseline differences among the cohorts.

In conclusion, in patients hospitalized with acute medical illness, those with asymptomatic proximal DVT have a 2-fold increase in mortality through day 90 compared with patients without VTE. Asymptomatic proximal DVT is an indicator of clinically important venous thromboembolic disease and is a useful outcome for evaluating efficacy in clinical trials of thromboprophylaxis in patients with acute medical illness.
REFERENCES

1. Sperry K, Key C, Anderson R. Toward a population-based assessment of death due to pulmonary embolism in New Mexico. _Hum Pathol._ 1990;21:159–165. DOI: 10.1016/0046-8177(90)90124-N.

2. Cohen AT, Edmondson RA, Phillips MJ, Ward VP, Kakkar VV. The changing pattern of venous thromboembolic disease. _Haemostasis_. 1996;26:65–71.

3. Geerts WH, Bergqvist DH, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Physicians guidelines-based clinical practice guidelines (8th Edition). _Chest_. 2008;133:381–453. DOI: 10.1378/chest.08-0656.

4. Dentali F, Douketis J, Giannini M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. _Ann Intern Med._ 2007;146:278–289. DOI: 10.7326/0003-4819-146-4-20070220-00007.

5. Kearon C. Natural history of venous thromboembolism. _Circulation_. 2003;107:122–130. DOI: 10.1161/01.CIR.0000078464.82671.78.

6. Vaitkus P, Leizorovicz A, Cohen A, Turpie AGG, Olsson CG, Goldhaber SZ. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. _Thromb Haemost_. 2005;93:76–79. DOI: 10.1160/TH04-05-0323.

7. Kalayci A, Gibson C, Chi G, Yee M, Korijan S, Datta S, Nafee T, Gurin M, Harion A, Qamar I, et al. Asymptomatic deep vein thrombosis is associated with an increased risk of death: insights from the APEX trial. _Thromb Haemost_. 2018;118:2046–2052. DOI: 10.1055/s-0038-1675606.

8. Cohen AT, Spiro TE, Bülker HR, Haskell L, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. _N Engl J Med._ 2013;368:513–523. DOI: 10.1056/NEJMoa1110956.

9. Cohen AT, Spiro TE, Bülker HR, Haskell L, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos A, et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. _J Thromb Thrombolysis._ 2011;31:407–416. DOI: 10.1007/s11239-011-0549-x.

10. Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. _Semin Thromb Hemost._ 2002;28(suppl 2):3–13. DOI: 10.1055/s-2002-232112.

11. Torres-Macho J, Mancebo-Plaza AB, Crespo-Giménez A, Sanz de Barros MR, Bibiano-Guillén C, Fallos-Martí R, Calderón-Parrás J, de Miguel-Yanes JM. Clinical features of patients inappropriately undiagnosed of pulmonary embolism. _Am J Emerg Med._ 2013;31:1646–1650. DOI: 10.1016/j.ajem.2013.08.037.

12. Goldhaber SZ, Hennensch CH, Evans DA, Newton EC, Godeski JJ. Factors associated with correct antemortem diagnosis of major pulmonary embolism. _Am J Med._ 1982;73:822–826. DOI: 10.1016/0002-9343(82)90764-1.

13. Bounamaux H, Agnelli G. Symptoms and clinical relevance: a dilemma for clinical trials on prevention of venous thromboembolism. _Thromb Haemost._ 2013;109:585–588. DOI: 10.1160/TH12-08-0627.